Germany’s IQWiG Fells AstraZeneca’s Caprelsa Again, Proving Mortality Trumps All
This article was originally published in The Pink Sheet Daily
Executive Summary
AstraZeneca’s Caprelsa has failed to take advantage of a second assessment chance at IQWiG, and it seems clear the company and the assessor never saw eye-to-eye on trial design.
You may also be interested in...
Deal Watch: Boehringer’s Busy Week – An Acquisition, A Divestiture And A Discontinuation
Teva’s buyout of Allergan’s generics business should end speculation about a Teva/Mylan merger. A new Sanofi/Regeneron tie-up and an AstraZeneca divestiture to Sanofi’s Genzyme unit are among the latest developments in immuno-oncology.
Amended AMNOG Sees New Life Breathed Into Trajenta Reimbursement Bid In Germany
Changes to Germany’s drug reimbursement law have permitted Boehringer Ingelheim and Eli Lilly to submit an updated dossier for their oral therapy Trajenta, giving medicine makers who operate there hope that further positive amendments will occur.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.